Latest EVH news and sentiment

Evolent Health Shares Rise After Citigroup Upgrade

Citigroup Upgrades Evolent Health to Buy From Neutral, Adjusts PT to $6 From $6.75

Evolent Health, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EVH) 2026-08-10

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, while adjusted EBITDA guidance narrowed to $120 million–$135 million. The May launch of the Highmark partnership drove a 50% sequential increase in Performance Suite revenue to $485 million. Evolent reported encouraging early clinical and provider engagement, though the medical expense ratio rose to 95% due largely to higher reserves tied to the launch. Evolent announced an oncology agreement expected to generate about $300 million in annualized revenue and said AI automation, cost controls and maturing contracts should support 2027 revenue growth above 25% and adjusted EBITDA of at least $150 million at the midpoint. Evolent Health (NYSE:EVH) reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business. C

Evolent Health Inc (EVH) (Q2 2026) Earnings Call Highlights: Revenue Surges 31% and Guidance ...

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, while adjusted EBITDA guidance narrowed to $120 million–$135 million. The May launch of the Highmark partnership drove a 50% sequential increase in Performance Suite revenue to $485 million. Evolent reported encouraging early clinical and provider engagement, though the medical expense ratio rose to 95% due largely to higher reserves tied to the launch. Evolent announced an oncology agreement expected to generate about $300 million in annualized revenue and said AI automation, cost controls and maturing contracts should support 2027 revenue growth above 25% and adjusted EBITDA of at least $150 million at the midpoint. Evolent Health (NYSE:EVH) reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business. C

Evolent Health (NYSE:EVH) Reports Bullish Q2 CY2026, Stock Jumps 18.2%

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates